Peritoneal Cancer – Causes, Symptoms, Treatment

Sending
User Review
( votes)

Peritoneal Cancer/Peritoneal carcinomatosis (PC) generally refers to the metastatic involvement of the peritoneum. The name was first coined in 1931 by Sampson for the thorough description of metastatic involvement of the peritoneal stromal surface by ovarian cancer cells. Since then, it refers to almost any peritoneal metastatic deposits, metastatic cancer to the peritoneum is more common than a primary peritoneal malignancy. It often occurs with gastrointestinal or gynecological malignancies of advanced stages with locoregional involvement. This activity articulates how to evaluate for this condition properly, and highlights the role of the interprofessional team in caring for patients with this condition.

The peritoneum is a continuous membrane that covers the abdominal and pelvic cavities. Anatomically it has two layers that are, in and of themselves, continuous. One is the parietal peritoneum, which covers the inner surfaces of the abdominal and pelvic wall, and the other layer is the visceral peritoneum, which covers the abdominal organs and their suspending structures in the abdominopelvic cavity.[rx] The greater omentum, a prominent peritoneal fold, also referred to as the gastrocolic ligament,  has been referred to as a policeman of the abdomen, recognizing its role in containing inflammation and minimizing the spread of infection or local disease in the abdominopelvic cavity.  This unique nature of the omentum puts it at risk of involvement with any abdominal malignancies through the local disease spread.

The term peritoneal carcinomatosis (PC) generally refers to the metastatic involvement of the peritoneum. The name was first coined in 1931 by Sampson for the thorough description of metastatic involvement of the peritoneal stromal surface by ovarian cancer cells.[rx] Since then, it refers to almost any peritoneal metastatic deposits, metastatic cancer to the peritoneum is more common than a primary peritoneal malignancy. It often occurs with gastrointestinal or gynecological malignancies of advanced stages with locoregional involvement. Historically, the presence of metastatic deposits in the peritoneal cavity implied an incurable, fatal disease where curative surgical therapy was no longer a reasonable option. Newer surgical techniques and innovations in medical management strategies have dramatically changed the course of the disease over the past years. Effective treatment approaches have evolved, allowing for improvements in disease-free and overall survival.[rx]

Causes of Peritoneal Cancer

Peritoneal involvement is most common with cancers of the gastrointestinal (GI), reproductive, and genitourinary tracts. Ovarian, colon, and gastric cancers are by far the most common conditions presenting in advanced stages with peritoneal metastasis. Cancers involving other organs such as the pancreas, appendix, small intestine, endometrium, and prostate can also cause peritoneal metastasis, but such occur less frequently. While peritoneal carcinomatosis can arise from extra-abdominal primary malignancies, such cases are uncommon; and they account for approximately 10% of diagnosed cases of peritoneal metastasis.[rx] Examples include breast cancer, lung cancer, and malignant melanoma. Ovarian cancer is the most common neoplastic disease-causing peritoneal metastasis in 46% of cases owing to the anatomic location of the ovaries and their close contact with the peritoneum as well as the embryological developmental continuity of ovarian epithelial cells with peritoneal mesothelial cells.[rx][rx]

  • Colorectal cancer patients also contribute to a higher number of patients with peritoneal involvement due to the high incidence of these cancers overall. About 7% of cases develop synchronous peritoneal metastasis.[rx]
  • Approximately 9% of non-endocrinal pancreatic cancer cases present with PC.
  • Gastric carcinoma tends to reach an advanced stage at first presentation, and 14% of such cases can have peritoneal metastasis.[rx]
  • A neuroendocrine tumor arising from the gastrointestinal tract (GI-NET) is a slow-growing neoplasm, and it can metastasize to the peritoneum. PC can occur in about 6% of GI-NET patients.[rx] Its frequency increases with age.
  • As described earlier, peritoneal carcinomatosis from extra-abdominal malignancy presents in only 10% of cases where metastatic breast cancer (41%), lung cancer (21%), and malignant melanoma (9%) account for the majority of the cases.[rx]
  • Lung cancer is the primary cause of newly diagnosed cancers worldwide, accounting for over a million new cases per year. However, peritoneal carcinomatosis in lung cancer is rare and occurs in about 2.5 to 16% of autopsy results. Considering the scale of lung cancer rates globally, it could be the reason for a higher number of peritoneal carcinomatosis cases worldwide.[rx]
  • Sometimes it is difficult to find the primary tumor site. In such cases, we have peritoneal carcinomatosis with an unknown primary (UP). About 3 to 5% of cases of peritoneal carcinomatosis are of unknown origin.[rx]

Cancer cell metastasis is a complex phenomenon involving a multistage process and multidirectional spread. Dissemination, adhesion, invasion, and proliferation are the significant steps for the development of peritoneal metastasis from any primary. Primary malignant cells can spread through local invasion, lymphatics, or blood to distal sites. In the case of peritoneal metastasis, malignant cells originating from primary abdominal organs usually spread through a transcoelomic mechanism. Peritoneal fluid cycles through the peritoneal cavity in a specific direction, and this could spread the cancer cells in a particular manner. Currently, extensive research has given more detailed knowledge about the pathophysiology of peritoneal metastasis. This complex process involves multilevel reactions among molecular and cellular components of the primary tumor site as well as the peritoneum. Peritoneal mesothelial cells provide adhesion to the invading cancer cells and stromal components, and endothelial cells help in proliferation.[rx] Paget’s original theory of “seed and soil” very well describes the pattern of peritoneal metastasis in cancers such as ovarian, colorectal, stomach, etc. It proposed that the organ-preference patterns of cancer metastasis are the product of favorable interactions between metastatic tumor cells (the “seed”) and their organ microenvironment (the “soil”), which several research studies have extensively demonstrated.[rx]

One theory describes that peritoneal carcinomatosis from gastrointestinal cancers can occur in two different ways: 1) Via transversal growth and 2) via the intraperitoneal spread. Transversal growth means tumor cells can exfoliate from the primary tumor into the peritoneal cavity, also known as synchronous peritoneal carcinomatosis. This variant usually occurs preoperatively. Intraperitoneal spread implies spread due to surgical trauma, where tumor cells get released unintentionally from transected lymph node or blood vessel or upon manipulation of the primary tumor during handling, referred to as metachronous peritoneal carcinomatosis. The most common dissemination of malignant cells in the peritoneum are with spontaneous exfoliation. Leucocyte-associated adhesional molecules like CD44, selectins, and/or integrin have been identified for cancer cell adhesion. Peritoneal stroma is the rich source for all the necessary factors required for proliferation.[rx]

You Can Also Like   Peritoneal Metastases - Causes, Symptoms, Treatment

Hematogenous spread involving the peritoneal cavity can occur in patients with malignant melanoma, lung, and breast cancer. In such cases, the embolic metastatic focus begins as a small nodule with eventual progression. The lymphatic spread usually revolves around the ligaments and mesentery, and such dissemination can occur in non-Hodgkin lymphoma or neuroendocrine tumor (NET).

Biological research describes three types of peritoneal cancer spread, which is helpful to understand to guide surgical management:

  • Random Proximal Distribution (RPD): Typically occurs in moderate and high-grade cancers in their early implantation due to the adherence molecules on the cancer cells near the tumor area. Examples include adenocarcinoma and carcinoid of an appendix, non-mucinous colorectal cancer, gastric cancer, and serous ovarian cancer.
  • Complete Redistribution (CRD): Here, there is no adhesion with the peritoneum near the primary tumor due to the low biological activity of the cancer cells. Examples are pseudomyxoma peritonei, diffuse malignant mesothelioma.
  • Widespread Cancer Distribution (WCD): The presence of adherence molecules on the cancer cells, along with mucus production, leads to the aggressive and widespread dissemination of cancer. Examples in this category include mucinous colorectal cancer, mucinous ovarian cancer, cystadenocarcinoma of the appendix.

This understanding of the pattern of spread helps in determining the best surgical approach: RPD treatment is best via selective peritonectomy of macroscopically involved regions. While CRD and WCD treatment should be with complete peritonectomy and extensive cytoreduction therapy.[rx]

Complications related to peritoneal metastases:

  • Ascites: Peritoneal metastases tend to produce fluid in the abdomen, known as ascites, which causes abdominal distension (Figure 2).
  • Intestinal obstruction: Peritoneal metastases may cause blockage of the intestines.
  • Hydronephrosis: The kidney ureters may be blocked by peritoneal metastases. This may affect kidney function.
  • Bloating
  • Abdominal pain
  • Nausea and vomiting
  • Constipation
  • Loss of appetite
  • Weight loss

Diagnosis of Peritoneal Cancer

Patients with peritoneal metastasis usually present in a late stage of the disease. They typically present with symptoms and signs associated with their advanced primary cancer, or often peritoneal carcinomatosis is an accidental finding during surgical exploration for primary tumor resection or during other elective procedures. The two most important clinical findings related to peritoneal carcinomatosis have been ascites and bowel obstruction. However, they are found clinically in less than 50% of patients.[rx][rx] Similar to any other cancer, patients may complain of loss of appetite, organ-specific symptoms such as abdominal pain, nausea, vomiting, constipation, abdominal distension, weight loss, etc. Two main clinical features that could raise the suspicion for peritoneal metastasis include 1) the presence of malignant cells in ascitic fluid (28% to 30% of colorectal peritoneal metastasis patients), and 2) bowel obstruction (8% to 20% of patients with colorectal peritoneal metastasis.[rx]

Given the non-specific clinical picture associated with patients with peritoneal metastasis, it is highly unpredictable and difficult to diagnose this condition just based on clinical presentation. However, whenever there is a finding suggesting the possibility of abdominal cancer, clinicians should keep a low threshold for considering the presence of advanced-stage disease, as evidenced by the presence of peritoneal metastasis, even when imaging does not show readily show this. The peritoneum and any ascitic fluid can undergo an examination at the time of surgical exploration during a planned or emergent procedure.

Lab Test and Imaging

Metastatic cancer of the peritoneum is often an incidental finding detected during surgical exploration or on diagnostic imaging with modalities like CT scan or MRI performed for other indications. Biopsy of detected tumors or lesions is a confirmatory test to identify the type of cancer cells and to differentiate it from primary peritoneal cancer.

 The primary objectives of the work-up and investigation modalities employed in cases of suspected peritoneal metastasis are the following:

  • Early detection of possible peritoneal metastasis in a patient with recently diagnosed abdominal or pelvic malignancy and to rule out the presence of distant metastases in extra-abdominal areas, which becomes an absolute contraindication for surgery with curative intent.
  • To determine the extent, size, and major organ involvement by metastatic cancer to decide proper patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Early staging of the PC to help ascertain valuable information about potential outcomes and predict prognosis after treatment.

Cancerous lesions involving the peritoneum are sometimes visible with CT Scan, MRI, and 18F-fluorodeoxyglucose (FDG) positron emission tomography PET/CT. Each modality has its importance depending on the type of cancer and area of involvement. Presently the peritoneal carcinomatosis index (PCI) scoring system proposed by Dr. Sugarbacker provides a useful tool for better patient selection for surgery and a better understanding of prognosis and outcome (described in the management and staging section below). So most of the imaging studies are employed for their diagnostic parameters based on how accurately they can contribute to the PCI score preoperatively.[rx]

  • Ultrasound – Malignant ascites may be anechoic or have low-level echoes, and aids in the identification of deposits . Nodules are of intermediate echogenicity, hypoechoic compared to the peritoneum, whereas infiltration of the omentum results in hyperechogenicity.
  • CT Scan – It can provide appropriate site-specific cancer involvement in the abdominal cavity. The crucial findings for peritoneal metastasis are focal or diffuse thickening of peritoneal folds, which could appear as sclerotic, nodular, reticular, reticulonodular, or large plaque-like structures. Sometimes a large, thick layer of inhomogeneous density would be visible between the abdominal wall and bowel loops, which is sometimes called an “omental cake.” It is a neoplastic tissue layer. CT will also detect micronodules and micronodules if they are lying at the surface of the liver or spleen. Ascites can also be detected if it is over 50 ml.[rx] The sensitivity of computed tomography scan of the abdomen and pelvis for the diagnosis of colorectal cancer-related PM is 90% for cancer nodules larger than 5 cm but drops to less than 25% for lesions smaller than 5 cm.[rx] CT scan used for the detection of peritoneal tumors for future management decisions was also found to have inter-observer differences among radiologists and is not considered as the most reliable tool for the same.[rx] Additionally, CT is inefficient in assessing small bowel lesions, which could underestimate the PCI score preoperatively. However, it is still a valid tool to achieve optimal cytoreduction in cases of ovarian metastasis with moderate accuracy.[rx] Currently, abdominopelvic CT scanning is the first line of investigation for the detection of peritoneal metastasis in the presence of any abdominal primary.
    Peritoneal metastases can range in appearance from invisible to multiple large masses, and historically CT can only detect 60-80% of peritoneal metastases later shown to be present at surgery, although more recent studies reported detection rates of 85-93% 1,3. Appearances include 1:

    • thickening and enhancement of peritoneal reflections (especially if nodular)
    • soft tissue nodulesstranding and thickening of the omentum (omental cake)
    • stranding and distortion of the small bowel mesentery
    • ascites, especially if loculated
    • calcifications 2 (particularly in cystadenocarcinoma of the ovary)
      • nodular with the non-calcified component are typical
      • nodal calcification

    Intraperitoneal contrast has been investigated as a way of improving sensitivity to the presence of small deposits, and may improve detection but has not been widely adopted 3.

  • MRI – It is also one of the diagnostic tools for detecting peritoneal metastasis. However, it has not shown any significant superiority over CT scanning. One study did demonstrate an advantage of MR over single-helical CT for the detection of metastasis over peritoneum, omentum, and bowel.[rx] The combined use of MRI and CT has improved the preoperative estimation of PCI compared to only CT-determined PCI.[rx] Diffuse weighted MRI is used more for its diagnostic parameters, and one recently published study showed significant results. Whole-body diffuse weighted imagine-MRI (WB-DWI/MRI) was significantly better in the prediction of inoperability for peritoneal carcinomatosis than CT with sensitivity 90.6%, specificity 100%, PPV 100%, and NPV 90.3%. For CT alone these values were 25.0, 92.9, 80.0 and 52.0%, respectively.[rx]
  • PET Scan – The use of a PET-CT scan is more useful than just a PET scan, as the addition of CT allows for better anatomic visualization. 18F-fluorodeoxyglucose (FDG) positron emission tomography PET/CT is the preferred imaging that can detect the presence of cancer lesions based on the glucose uptake of the cells. It can be falsely negative when cells do not show good glucose uptake. Thus in cases where it is used for postoperative imaging, it would be better to document preoperative results for comparison to avoid false-negative results.[rx] To identify the exact localization and area of the peritoneal metastasis, PET-CT provides better accuracy and especially better NPV than MRI.[rx] PET-CT adds good value to conventional imaging mainly for monitoring response to the therapy, especially on long-term follow-up.[rx]
  • Diagnostic Laparoscopy – Surgeons recommend preoperative use of diagnostic laparoscopy for the assessment of the resectability of peritoneal tumor nodules before undergoing cytoreductive surgery (CRS). This approach is useful in patients for whom the previous imagining studies are insufficient in providing adequate information about the extent of disease involvement. However, it is sometimes not favored due to the difficulty related to trocar insertion and fear of port-site tumor recurrence. But currently, many surgeons are advocating its important role in affirmative decision making before actually going for laparotomy. In one study, it was found to have a positive predictive value of 83.3%. It also helped to avoid unnecessary laparotomy in 45% of the cases with no port-site recurrences or morbidity after 18 months.[rx] Similarly, another study suggested detailed technical aspects of the diagnostic laparoscopy, with over 94% of confirmative findings with the use of only two trocars and 99% for all cases.[rx] Extensive studies would be needed to get more evidence for its routine practical use.

New Proposed Diagnostic Methods

Different surgeon groups have proposed new diagnostic techniques for the optimum detection of peritoneal carcinomatosis and a more accurate understanding of its extent and size before considering surgical exploration:

  • Detection of ascitic CEA (carcinoma embryonic antigen) is a useful measure for diagnosing colorectal cancer (CRC) with PM.[rx]
  • Extensive involvement of small bowel by peritoneal carcinomatosis precludes the use of cytoreductive surgery. CT lacks sufficient accuracy in preoperative detection of disease in the small intestine that may subsequently impact the decision to offer CRS. One group of researchers demonstrated that CT-enteroclysis (CTE) is very useful in detecting cancerous implants in small bowel/mesentery. It showed 92% sensitivity, 96% specificity, 97% PPV and 91% NPV.[rx]
  • Another group of investigators explored the use of single-incision flexible endoscopy (SIFE) for diagnostic staging before surgery, and they compared it to rigid endoscopy (SIRE). The major objective was to avoid trocar site metastasis by reducing the need for extra trocar usage. The study showed feasibility in 94% of cases with SIFE and demonstrated superiority to SIRE in terms of technical exploration and outcomes. Future studies are needed to compare this with conventional laparoscopy.[rx]

Treatment of Peritoneal Cancer

Recent advancements in surgical techniques and favorable outcomes related to targeted chemotherapy have encouraged the aggressive treatment of PC whenever it is feasible and accessible. Complete cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic chemotherapy has become the mainstay treatment for peritoneal carcinomatosis (PC) originating from most gastrointestinal and genitourinary tracts carcinomas. The efficacy of this treatment was validated in 2003 by a randomized clinical trial that compared CRS combined with HIPEC versus systemic chemotherapy alone (median survival: 22.3 vs. 12.6 months, P = 0.032).[rx] Macroscopically complete CRS (CRS-R0) is a major prognostic factor, with 5-year survival rates as high as 45% compared to less than 10% when CRS is incomplete.[rx] Dr. Sugarbaker changed the perception relating to peritoneal carcinomatosis from being terminal cancer to being a loco-regional disease and recommended an aggressive surgical approach with CRS, given the positive survival benefits.

The first step in the management centers is the appropriate patient selection for surgery.

Patient selection

  • Patient characteristics: age, comorbidities, general condition, and functional status. The objective is to determine the fitness of the patient for the anticipated trauma of surgery and its perioperative impact.
  • Exclude generalized metastatic disease: As pointed in the diagnostic section, CT and/or MRI or sometimes PET/CT can be used to investigate potential distal metastases depending on the type of cancer. Possible sites to look for are thorax, spine bones, brain, etc.
  • The extent of the peritoneal disease:

CT/MRI is the primary investigation tool to determine the size, extent, and type of peritoneal lesions. PCI scoring system described in figure 1 is routinely used to determine the surgical resectability and possibly favorable prognosis. Diagnostic laparoscopy provides very accurate estimates for PCI along with probable completeness of the cytoreduction (CC) index and outcome assessment in terms of disease-free survival, overall survival, and quality of life. The involvement of the small bowel impacts the PCI score and can suggest a bad prognosis. The following are the usual surgical sites used for preoperative determination of the extent of the disease for exclusion from CRS. [rx]

  • Massive mesenteric root infiltration not amenable to complete cytoreduction
  • Significant pancreatic capsule infiltration or pancreatic involvement requiring major resection not feasibly or amenable to complete surgical cytoreduction
  • More than one-third of small bowel length involvement requiring resection
  • Extensive hepatic metastasis

Some surgeons advocate the use of peritoneal surface disease severity score (PSDSS) for the early preoperative assessment of the prognosis based on the symptoms, PCI index, and primary tumor histology. However, extensive study results are needed to implement it in regular practice.[rx]

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy

Upon the determination of patient fitness for surgery with selection driven by feasibility criteria, CRS is performed commonly through an open abdominal wall incision approach along with perioperative intraperitoneal chemotherapy. This novel treatment option became a reality for surgeons through the extensive work of Dr. Sugarbacker[rx] and his suggested surgical techniques. Cytoreductive surgery includes peritonectomy and individualized manual resection of the tumor lesions from different areas of the abdominal wall and mesentery. Peritonectomy now classifies as a curative treatment method for patients with peritoneal carcinomatosis, with the latter viewed as the locoregional spread instead of systemic disease. The usual surgical intention for any cancer treatment is the removal of all cancer cells through en-block resections with clear margins. However, for peritoneal carcinomatosis, it is highly difficult to achieve the complete removal of malignant cells. The idea behind cytoreduction is to reach complete removal of any macroscopic lesions, and the simultaneous use of HIPEC would potentially remove microscopic cancer lesions.[rx][rx] This technical approach has shown tremendous survival benefits along with disease-free survival and improved quality of life in patients. Currently, CRS combined with HIPEC is a first-line treatment for appendiceal and colorectal cancer-related PM.[rx][rx] It has also shown a promising role in ovarian, gastric, and neuroendocrine tumors.[rx][rx][rx] 

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)

This newer innovative therapeutic intervention has potential use in patients with extensive peritoneal carcinomatosis who may be deemed unresectable or unfit for surgery. The basis for aerosol chemotherapy is the premise that the intraabdominal application of chemotherapeutic drugs under pressure could potentially enhance tissue penetration and increases distribution.[rx] It has also been found to have superior benefits of drug delivery to tumor tissue with a significant effect on tumor regression than conventional intraperitoneal chemotherapy or systemic chemotherapy.[rx] This treatment option is beneficial in patients with extraperitoneal metastases in which this method could work as an effective palliative treatment option. Further ongoing prospective trials will decide on its future role and regular use.

​Peritoneal metastasis is difficult to treat and is best managed by a multi-disciplinary team that includes surgeons and medical oncologists.

  • Systemic chemotherapy: Chemotherapy drugs given intravenously or sometimes in combination with oral tablets circulate through the whole body. This type of treatment is suitable for cancers that have metastasized to multiple parts of the body.
  • Cytoreductive Surgery (CRS) with Hyperthermic intraperitoneal Chemotherapy (HIPEC):
    CRS is an extensive surgery that removes all visible cancers within the abdominal cavity. At the end of CRS, a heated chemotherapy solution is applied to the peritoneal cavity to destroy the remaining cancer cells that cannot be seen with the naked eye.
  • Intra-peritoneal (IP) chemotherapy: IP chemotherapy (Figure 3) is injected into the peritoneal cavity via an intraperitoneal port that is inserted via keyhole surgery. The port is buried under the skin and connected to a catheter that enters the peritoneal space.
  • Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC): PIPAC (Figure 4) is a novel method of delivering chemotherapy directly into the peritoneal cavity in an aerosol form. It utilizes the physical properties of pressurized gas to distribute the drug evenly and deeply. This allows greater penetration of the drug into the cancer cells, with reduced systemic side effects of the chemotherapy agent. PIPAC is performed as a short and simple laparoscopic (keyhole) surgery. Under general anesthesia, small instruments will be placed into the abdomen. A micro-pump will deliver the chemotherapy drug into the peritoneal cavity as an aerosol. At the end of the procedure, any residual gas within the peritoneal cavity will be removed.

Currently, PIPAC is a minimally invasive palliative procedure that aims to prolong survival and preserve the quality of life. Due to the low dosage applied, PIPAC can be combined with systemic palliative chemotherapy and has minimal organ toxicity. This procedure can be repeated at intervals of 6 weeks to 3 months.

PIPAC GIF (Infinity Loop).gif

Figure 4: Set-up of Pressurised Intra-Peritoneal Aerosol Chemotherapy (PIPAC)

Video Demonstration of PIPAC treatment

 

Print Friendly, PDF & Email